Liposarcoma

• Age: middle-aged and older adults; rare in children.
• Site: the retroperitoneum and the deep soft tissues of the thigh and limbs. Retroperitoneal tumours grow silently and may reach enormous size before causing mass effect, early satiety, or pain.
• Subtypes with distinct behaviour:
• Well-differentiated (atypical lipomatous tumour) — commonest, locally recurrent but non-metastasising, characterised by MDM2 and CDK4 amplification.
• Dedifferentiated — arises from a well-differentiated component and metastasises.
• Myxoid/round cell — younger adults, t(12;16) FUS–DDIT3, with a characteristic tendency to metastasise to other soft-tissue sites rather than lung.
• Pleomorphic — least common, most aggressive.
• Distinguishing from lipoma is the everyday task: features favouring sarcoma are size above about 5 cm, depth to the fascia, rapid growth, pain, and on MRI thick septa, nodularity and enhancing non-fatty components.
• Management is wide surgical excision; radiotherapy is used for local control in selected cases, and conventional chemotherapy has limited activity in the well-differentiated subtypes.

Non-modifiable / genetic

• Sporadic somatic amplification: the great majority are sporadic. Well-differentiated and dedifferentiated tumours carry amplification of the 12q13-15 region (containing MDM2 and CDK4) as supernumerary ring or giant marker chromosomes — a cytogenetic signature with no known environmental trigger.
• Balanced translocation: myxoid/round cell liposarcoma arises from t(12;16)(q13;p11) generating the FUS–DDIT3 (CHOP) fusion; a minority carry the variant EWSR1–DDIT3 translocation. These are early, initiating events, not the consequence of an exposure.
• Cancer predisposition syndromes: Li-Fraumeni syndrome (germline TP53) and hereditary retinoblastoma (germline RB1) confer excess soft-tissue sarcoma risk broadly; these are the syndromes examiners plant when a stem mentions early-onset cancers in multiple relatives.
• Age and sex: incidence rises through middle age with a modest male predominance; myxoid subtype skews younger (third to fifth decades).

Modifiable / acquired

• Prior therapeutic radiation: the best-established acquired risk factor for soft-tissue sarcoma in general, with a latency typically measured in years to decades and tumour arising within the treated field. Dedifferentiated and pleomorphic histologies predominate in radiation-associated disease.
• Occupational or environmental exposures: associations with agents such as vinyl chloride and thorotrast are classic for hepatic angiosarcoma rather than liposarcoma; do not over-attribute.

Common distractors that are not risk factors

• Trauma: a remembered blow to the thigh is recall bias — trauma draws attention to a pre-existing mass, it does not cause it.
• Obesity or a high-fat diet: adiposity does not drive adipocytic sarcoma.
• Pre-existing lipoma: liposarcoma does not arise from malignant transformation of an ordinary lipoma; the two are genetically distinct from the outset.
• Chronic lymphoedema: this is the setup for Stewart-Treves angiosarcoma, not liposarcoma.

The initiating genetic lesion determines subtype behaviour

• MDM2/CDK4 amplification (well-differentiated and dedifferentiated): amplified MDM2 is an E3 ubiquitin ligase that binds and degrades p53, functionally silencing the p53 checkpoint without mutating the gene itself. Co-amplified CDK4 phosphorylates Rb, releasing E2F and driving G1→S transit. The result is unchecked proliferation of adipocytic precursors with retained differentiation — hence a tumour that still looks like fat and behaves as a locally infiltrative, non-metastasising lesion (atypical lipomatous tumour when in the extremity).
• Dedifferentiation: accumulation of additional genomic hits within a well-differentiated tumour produces an abrupt transition to a high-grade, non-lipogenic sarcoma. This explains the classic imaging pattern of a nodular soft-tissue mass embedded within an otherwise fatty tumour, and it is why the dedifferentiated component, not the fatty one, metastasises.
• FUS–DDIT3 fusion (myxoid): the fusion protein is an aberrant transcription factor that blocks C/EBP-driven adipocytic maturation, arresting cells at the lipoblast stage within an abundant myxoid matrix supplied by a delicate "chicken-wire" plexiform capillary network. Maturation arrest, not lipogenesis, is the defect.

Why the clinical picture follows from this

• Retroperitoneal silence: the retroperitoneum is a compliant potential space with no serosal pain fibres; tumours enlarge for months to years before displacing bowel, ureter, or IVC. Symptoms are therefore those of mass effect — early satiety, hydronephrosis, venous congestion — not of the tumour itself.
• Death by local recurrence: well-differentiated retroperitoneal disease infiltrates along fascial planes and abuts unresectable structures, so repeated local regrowth, not distant spread, drives mortality.
• Odd metastatic pattern in myxoid disease: the fusion-driven phenotype favours seeding of other fatty and soft-tissue sites and bone marrow (spine, retroperitoneum, axilla) rather than lung, which is why chest CT alone under-stages it.

Extremity / trunk disease

• Painless deep mass: fat is compressible and the deep compartment accommodates growth, so the lesion is typically firm, fixed, deep to the investing fascia, and >5 cm at presentation.
• Pain or neurological deficit: a late finding, signalling compression or invasion of a named nerve or perineural extension; paraesthesias in a nerve distribution should raise suspicion rather than reassure.
• Rapid enlargement or a mass that becomes painful: suggests a dedifferentiated focus or intratumoural haemorrhage.
• Overlying skin is usually normal — ulceration and warmth point elsewhere.

Retroperitoneal disease (grows silently, presents by mass effect)

• Early satiety, nausea, abdominal distension: gastric and small-bowel displacement.
• Flank pain, hydronephrosis: ureteral encasement.
• Lower-limb oedema, dilated abdominal wall veins: IVC or iliac vein compression.
• Unilateral leg pain or weakness: lumbosacral plexus involvement.
• Palpable abdominal mass that is non-tender and crosses the midline; the mass may be missed on examination in obese patients until it is very large.
• Constitutional symptoms (weight loss, fever) are uncommon — their absence does not argue against malignancy here.

Step 1 — imaging before any instrument touches the mass

• MRI with contrast is the initial study for an extremity or truncal mass (ACR Appropriateness Criteria). A simple lipoma follows subcutaneous fat on every sequence and suppresses completely on fat-saturated images. Features favouring liposarcoma: thick (>2 mm) or nodular septa, enhancing non-fatty components, size >5 cm, and location deep to the investing fascia.
• Contrast-enhanced CT of the abdomen and pelvis is the workhorse for retroperitoneal disease, showing a large fat-density mass, often with a distinct soft-tissue nodule within fat — the imaging signature of a dedifferentiated component.

Step 2 — biopsy, done correctly

• Image-guided core-needle biopsy is the standard, per NCCN, ideally performed at or in consultation with the sarcoma centre that will operate. The tract must be placed so it can be excised en bloc with the specimen.
• Do not perform excisional biopsy, enucleation, or transperitoneal biopsy of a resectable retroperitoneal mass; FNA is inadequate for grading and typing.

Step 3 — pathology and molecular confirmation

• Histology: lipoblasts (scalloped, hyperchromatic nuclei indented by cytoplasmic lipid vacuoles) are classic but neither required nor specific. Myxoid tumours show a "chicken-wire" plexiform capillary network; a round-cell component denotes higher grade.
• MDM2/CDK4 FISH or immunohistochemistry is the decisive test separating atypical lipomatous tumour/well-differentiated liposarcoma (amplified) from lipoma (not amplified) — the single most useful ancillary study.
• DDIT3 rearrangement (FUS–DDIT3) confirms myxoid liposarcoma.

Step 4 — grading and staging

• FNCLCC grade (differentiation, mitotic count, necrosis) feeds the AJCC TNM staging system, which is site-specific for soft-tissue sarcoma.
• CT chest for pulmonary metastases. For myxoid histology add imaging of the abdomen/pelvis and spine (MRI) because of the extrapulmonary metastatic pattern.

Before anything else

• Refer to a multidisciplinary sarcoma centre before biopsy or resection — NCCN states this explicitly, because an unplanned "whoops" excision contaminates tissue planes and worsens local control.
• Emergency stabilisation is rarely needed but applies to bowel obstruction, ureteral obstruction with obstructive nephropathy, or tumour haemorrhage.

Definitive therapy — surgery is curative-intent in all resectable disease

• Wide en bloc resection with negative margins: for the extremity this means limb-sparing resection through uninvolved tissue; for the retroperitoneum it often means compartmental resection with adjacent viscera (kidney, colon, psoas) to achieve a clear margin.
• Contraindicated: enucleation or "shelling out", morcellation, and intralesional resection — all guarantee recurrence.

Radiotherapy (local control, not survival in most settings)

• Extremity high-grade or large (>5 cm) tumours: pre- or postoperative external-beam RT per NCCN. Preoperative RT uses a lower dose and smaller field but carries higher acute wound-complication rates; postoperative RT spares the wound at the cost of a larger field and more late fibrosis.
• Myxoid/round cell liposarcoma is notably radiosensitive, often showing marked shrinkage after preoperative RT.
• Retroperitoneal disease: routine preoperative RT is not recommended outside a clinical trial, as the randomised STRASS trial did not demonstrate improved abdominal recurrence-free survival.

Systemic therapy (advanced, metastatic, or selected high-risk disease)

• Anthracycline-based cytotoxic therapy is first-line: doxorubicin, alone or with ifosfamide when response is the goal.
• Second-line agents with specific liposarcoma activity: trabectedin and eribulin, both FDA-approved after prior anthracycline; eribulin's benefit is strongest in the liposarcoma subset.
• Gemcitabine-based regimens are an alternative.
• Well-differentiated liposarcoma is essentially chemoresistant — do not treat it with cytotoxics; surveillance or re-resection is the answer.
• CDK4 inhibitors and MDM2 antagonists exploit the amplicon and remain investigational.

Disease-related

• Local recurrence: the dominant problem, especially retroperitoneal well-differentiated tumours, which recur repeatedly along fascial planes and ultimately cause death by unresectable local disease rather than metastasis. Signalled by a new soft-tissue nodule on surveillance CT.
• Dedifferentiation: a well-differentiated tumour that suddenly grows or becomes painful, with a non-fatty enhancing nodule on imaging, has acquired metastatic potential.
• Mass-effect syndromes — emergencies: bowel obstruction or perforation, ureteric obstruction with acute kidney injury and hydronephrosis, IVC compression with lower-limb oedema and risk of venous thromboembolism.
• Tumour rupture or intratumoural haemorrhage: sudden pain, expanding mass, falling haematocrit — emergency.
• Metastatic disease: lung for dedifferentiated/pleomorphic; soft tissue, retroperitoneum and spine for myxoid. Vertebral or epidural myxoid metastasis causing cord compression is a neurosurgical emergency — new back pain with myelopathic signs warrants urgent MRI and corticosteroids.

Treatment-related

• Surgical: wound dehiscence and infection (markedly increased after preoperative radiotherapy, particularly in the thigh), lymphoedema, nerve sacrifice with motor deficit, and — after retroperitoneal resection — single-kidney physiology, anastomotic leak, and chylous ascites.
• Radiotherapy: late fibrosis, joint contracture, and limb dysfunction; insufficiency fracture of the irradiated bone; and, at long latency, a radiation-induced secondary sarcoma within the treated field.
• Doxorubicin: dose-dependent cardiomyopathy from topoisomerase-IIβ inhibition and reactive oxygen species — monitor LVEF; a falling ejection fraction mandates a change in plan. Extravasation is a vesicant emergency.
• Ifosfamide: haemorrhagic cystitis from acrolein (prevented with mesna and hydration), plus encephalopathy and renal tubular injury (Fanconi syndrome).
• Myelosuppression with neutropenic fever — an emergency requiring prompt empiric broad-spectrum antibiotics.

• A deep mass >5 cm or one that is growing is a sarcoma until proven otherwise. The single best next step is MRI with contrast (or CT for a retroperitoneal mass), then image-guided core-needle biopsy at a sarcoma centre — never excisional biopsy, never enucleation.
• MDM2 and CDK4 amplification is the association examiners test most: it distinguishes atypical lipomatous tumour / well-differentiated liposarcoma from a benign lipoma on FISH. Amplified MDM2 degrades p53 without any TP53 mutation.
• t(12;16) FUS–DDIT3(CHOP) = myxoid liposarcoma, younger adults, "chicken-wire" capillary network, radiosensitive and chemosensitive, and metastasises to other soft-tissue sites and the spine rather than lung — so chest CT alone under-stages it.
• Lipoblast is the classic buzzword (scalloped nucleus indented by lipid vacuoles) but it is neither required for the diagnosis nor specific to it.
• Retroperitoneal well-differentiated liposarcoma kills by local recurrence, not metastasis — hence the emphasis on complete en bloc resection, often with adjacent organs, per NCCN.
• A new enhancing non-fatty nodule within a fatty mass = dedifferentiation and confers metastatic potential.
• Common distractor 1: liposarcoma does not arise from a pre-existing lipoma; they are genetically distinct lesions.
• Common distractor 2: trauma, obesity, and dietary fat are not causes. The one credible acquired risk factor is prior therapeutic radiation.
• Common distractor 3: chemotherapy for well-differentiated disease — it is essentially chemoresistant. Reserve doxorubicin (± ifosfamide), then trabectedin or eribulin, for advanced dedifferentiated, myxoid/round cell, or pleomorphic disease.